Zacks investment search upgrades icon (NASDAQ: ICLR) to buy

Icon (NASDAQ: ICLR) a holdback rating to a purchase note in a research report report released on Thursday, July 5, they currently have a target price of $ 147.00 on the stock of medical research company

According to Zacks , "ICON plc is a full service global clinical research organization. "

A number of other research badysts have also published reports on the company: BidaskClub put Icon on credit rating in a report on Friday, March 9. Icon price target at $ 150.00 and gave the stock a purchase note in a search report on Friday, June 1 KeyCorp increased its price target on Icon from $ 130.00 to $ 152.00 and gave an overweight rating to a researcher ort on Monday, June 18th. Finally, Credit Suisse Group raised its price target on Icon from $ 131.00 to $ 144.00 and awarded it an outperformance rating in a research report on Tuesday, June 19th. Two research badysts rated the stock with a reserve rating, nine gave a purchase rating and one gave a strong buy-to-action rating. The stock has a buy consensus rating and an average target price of $ 138.80.

Icon dropped $ 3.86, reaching $ 141.00, during the trading day Thursday, reports Marketbeat.com. 447,183 shares were exchanged, compared with an average volume of 238,085. The company has a market capitalization of $ 7.63 billion, a price / earnings ratio of 26.16, a PEG ratio of 2.21 and a beta of 0.45. The icon has a minimum of 52 weeks and a minimum of 52 weeks of $ 146.31. The company has a current ratio of 1.85, a ratio of 1.85 and a debt ratio of 0.29.

Icon (NASDAQ: ICLR) last announced its quarterly earnings data on Wednesday, July 25. The medical research company reported $ 1.31 in earnings per share (EPS) for the quarter, missing the consensus estimate of $ 1.48 per ($ 0.17). The company achieved a business turnover of $ 641.60 million during the quarter, compared with $ 618.64 million for badysts. Icon had a net margin of 13.69% and a return on equity of 26.71%. The quarterly business turnover of the company is up 48.9% over the same quarter of last year. During the same period of the previous year, the company posted a profit of $ 1.34 per share. Equity badysts expect Icon to post EPS 6.08 for the current fiscal year.

A number of institutional investors and hedge funds recently bought and sold shares of ICLR. SPF Beheer BV bought a new position in Icon shares during the fourth quarter of about $ 92,565,000. Boston Partners increased its stake in Icon shares by 46.3% in the first quarter. Boston Partners now holds 1,626,440 shares in the medical research business worth $ 192,147,000 after purchasing 514,715 additional shares during the period. WCM Investment Management CA increased its stake in Icon stocks by 4.2% in the first quarter. WCM Investment Management CA now holds 4,461,500 Medical Research Company shares worth $ 527,082,000 after purchasing an additional 180,289 shares during the period. Principal Financial Group Inc. increased its stake in Icon's shares by 20.6% during the first quarter. Principal Financial Group Inc. now holds 946,806 medical research company shares worth $ 111,856,000 after purchasing 161,558 additional shares during the period. Finally, Lord Abbett & Co. LLC increased its stake in Icon shares by 49.5% during the first quarter. Lord Abbett & CO. LLC now holds 465,533 medical research company shares worth $ 54,998,000 after purchasing 154,094 additional shares during the period. Hedge funds and other institutional investors hold 87.10% of the shares of the company.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology and medical industries in Ireland, in the rest of the world. Europe, the United States and internationally. She specializes in the strategic development, management and badysis of programs that support various stages of the clinical development process, from selection of compounds to phase I to IV clinical studies

History: Qu & # 39; is a closed-end mutual fund?

Get a Free Copy of the Zacks Research Report on Icon (ICLR)

For more information on Zacks Investment Research's research offerings, visit Zacks.com [19659012] NASDAQ: ICLR) “title =” Recommandations d'badystes pour Icon (NASDAQ: ICLR) “/>

Receive News & Reviews for Icon Daily – Enter your email address below to receive a concise summary of the latest news and badyst feedback for Icon and Related Companies with Newsletter FREE daily email from MarketBeat.com.